Target intelligence / Profile preview

Gastrointestinal microbiota and mucosa

Molecular classification
Other
01

Overview

The gastrointestinal microbiota and mucosa constitute a complex biological system essential for maintaining systemic homeostasis and immune regulation. The microbiota comprises a diverse community of bacteria, archaea, fungi, and viruses, while the mucosa acts as a multi-layered barrier consisting of epithelial cells, a mucus layer, and underlying immune cells (Thursby & Juge, 2017, Biochem J). This system is responsible for the fermentation of non-digestible dietary fibers into short-chain fatty acids (SCFAs), the synthesis of vitamins, and the competitive exclusion of pathogenic microorganisms (Lynch & Pedersen, 2016, NEJM). Furthermore, the intestinal mucosa facilitates oral tolerance by preventing inappropriate immune responses to commensal microbes and food antigens while maintaining the ability to mount defenses against pathogens (Belkaid & Hand, 2014, Cell). Dysfunction within this system, often characterized by reduced microbial diversity (dysbiosis) and increased epithelial permeability, is a hallmark of numerous pathologies, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and metabolic syndrome (Turner, 2009, Nat Rev Immunol). Pharmacological and therapeutic interventions targeting this environment include probiotics and prebiotics to modulate microbial composition, as well as aminosalicylates and biologics designed to promote mucosal healing and restore barrier integrity (Okumura & Takeda, 2017, Exp Mol Med).

Other names
Gut microbiomeIntestinal floraGastric mucosaIntestinal barrierGut-microbiota-mucosa axis
02

Mechanism of action

Modulation of microbial populations, restoration of epithelial barrier function, suppression of mucosal inflammation, and competitive inhibition of pathogens.

03

Biological functions

Nutrient metabolismImmune system modulationBarrier functionPathogen protectionVitamin synthesisShort-chain fatty acid production
04

Disease associations

Inflammatory bowel diseaseIrritable bowel syndromeObesityMetabolic syndromeColorectal cancerCeliac diseaseClostridioides difficile infection
05

Safety considerations

Risk of systemic infection in immunocompromised patientsAntibiotic-induced dysbiosisTransfer of antibiotic resistance genesPotential for triggering autoimmune flares
06

Interacting drugs

Probiotics

9 more in the full profile.

07

Biomarkers

Fecal calprotectinMicrobial alpha diversityShort-chain fatty acid levelsZonulin

Beyond the preview

Go deeper on Gastrointestinal microbiota and mucosa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastrointestinal microbiota and mucosa.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call